Trials / Completed
CompletedNCT01301456
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
Conditions
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Placebo | Single subcutaneous injection of placebo |
| BIOLOGICAL | PF-04856883 | Single subcutaneous injection of PF-04856883 |
| BIOLOGICAL | PF-04856883 | Single subcutaneous injection of PF-04856883 |
| BIOLOGICAL | PF-04856883 | Single subcutaneous injection of PF-04856883 |
| BIOLOGICAL | Placebo | Single subcutaneous injection of placebo |
| BIOLOGICAL | PF-04856883 | Single subcutaneous injection of PF-04856883 |
| BIOLOGICAL | PF-04856883 | Single subcutaneous injection of PF-04856883 |
| BIOLOGICAL | PF-04856883 | Single subcutaneous injection of PF-04856883 |
| BIOLOGICAL | Placebo | Multiple weekly subcutaneous injections of placebo for 3 weeks |
| BIOLOGICAL | PF-04856883 | Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks |
| BIOLOGICAL | PF-04856883 | Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks |
| BIOLOGICAL | PF-04856883 | Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks |
| BIOLOGICAL | PF-04856883 | Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-12-01
- Completion
- 2012-04-01
- First posted
- 2011-02-23
- Last updated
- 2018-02-09
- Results posted
- 2018-02-09
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01301456. Inclusion in this directory is not an endorsement.